comparemela.com

Latest Breaking News On - For investor - Page 6 : comparemela.com

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomIan estepanSarepta therapeutics incCompensation committeeCommencement incentive planNasdaq listing ruleGrant datePrecision genetic medicine engineFor investor

Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher . Sarepta.

United statesTrademark officeRare pediatric disease priority review voucher programSarepta therapeutics incExchange commissionDrug administrationSarepta therapeuticsRare pediatric disease priority review voucherPrecision genetic medicine engineFor investorUnited states patentAnnual report

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomIan estepanSarepta therapeutics incCompensation committeeCommencement incentive planNasdaq listing ruleGrant datePrecision genetic medicine engineFor investor

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. (BUSINESS WIRE) Jun 30, 2023

United kingdomUnited statesTracy sorrentinoIan estepanCompensation committeeSarepta therapeutics incCommencement incentive planNasdaq listing ruleGrant datePrecision genetic medicine engineFor investorInvestor contactSarepta therapeuticsBusiness wire

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

ELEVIDYS (delandistrogene moxeparvovec-rokl) is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS ELEVIDYS is a one-time treatment designed to treat the underlying genetic cause of Duchenne Sarepta will host a conference call on June 22 at 4:30 p.m. ET

United statesDoug ingramJerry mendellTrademark officeSarepta therapeutics incDrug administrationExchange commissionSarepta therapeuticsBusiness wireGene therapyNationwide childrenPat furlongParent project muscularSerious liver injuryPrecision genetic medicine engineFor investor

vimarsana © 2020. All Rights Reserved.